Peptide Trainings

Semaglutide vs Tirzepatide vs Retatrutide

Compare single, dual, and triple incretin receptor research.

Semaglutide

The breakthrough GLP-1 agonist for sustainable weight loss

You have almost certainly heard of Semaglutide — it is the active ingredient in Ozempic and Wegovy. It works by mimicking a hormone your gut naturally releases after you eat, called GLP-1. That hormone tells your brain you are full and tells your pancreas to manage blood sugar. Semaglutide does the same thing, but lasts much longer in your body. The result is that people feel full sooner, eat less, and lose significant weight. It is one of the most studied and prescribed medications in the world right now. If you are wondering how it compares to newer options, see our <a href="/peptides/tirzepatide" class="text-[#1a4731] underline font-medium">Tirzepatide page</a> (dual GIP/GLP-1) and <a href="/peptides/retatrutide" class="text-[#1a4731] underline font-medium">Retatrutide page</a> (triple receptor) for the full GLP-1 family comparison.

Mechanism of action

Semaglutide activates GLP-1 receptors in three key places. In your brain, it dials down appetite and cravings. In your pancreas, it helps release insulin when blood sugar is high (and stops the hormone that raises blood sugar). In your stomach, it slows down how fast food moves through, which keeps you feeling full longer. All three effects work together to reduce how much you eat and how your body handles the calories you do consume.

Benefits discussed in research

  • Significant and sustained weight loss (15–20% body weight)
  • Reduces appetite and food cravings
  • Improves blood sugar regulation
  • Cardiovascular risk reduction
  • Slows gastric emptying
  • FDA approved for type 2 diabetes and obesity

Research status

FDA Approved

Dosing information

For educational and research purposes only. Not medical advice.

typical
0.5–2.4 mg per week
range
0.25 mg (starting) to 2.4 mg (maintenance)
frequency
Once weekly
route
Subcutaneous injection
cycleLength
Ongoing (chronic use)
notes
Dose is titrated up slowly over 16–20 weeks to minimize GI side effects. Must be prescribed by a physician.

Side effects and safety

  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Potential pancreatitis (rare)
  • Thyroid C-cell tumors (theoretical, based on animal studies)

Frequently asked questions

Do I need a prescription for semaglutide?

Yes. Brand-name Semaglutide (Ozempic and Wegovy) requires a prescription from a licensed provider. Compounded versions have been available through telehealth platforms, but their legal status has been changing. Always check current regulations and work with a licensed provider.

Will I regain weight if I stop semaglutide?

Most people do regain weight after stopping, and clinical trials confirm this. Semaglutide manages your appetite and blood sugar signals — when you stop, those signals return to their previous levels. This is why building sustainable eating habits while on it matters so much. It works best as a tool to reset your relationship with food, not as a permanent solution on its own.

How does Semaglutide compare to Tirzepatide (Mounjaro/Zepbound)?

Tirzepatide targets two receptors (GLP-1 and GIP) while Semaglutide targets only GLP-1. In the SURMOUNT-5 head-to-head trial, Tirzepatide produced 47% more weight loss than Semaglutide 2.4mg. If you are looking for the next step up, see our full <a href="/peptides/tirzepatide" class="text-[#1a4731] underline font-medium">Tirzepatide profile</a> or the <a href="/compare/retatrutide-vs-tirzepatide" class="text-[#1a4731] underline font-medium">Retatrutide vs. Tirzepatide comparison</a>.

Research references

Read the Semaglutide profile

Tirzepatide

The dual-receptor agonist that outperformed every GLP-1 drug in clinical trials

Tirzepatide is the active ingredient in Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It is the first drug ever approved that targets two hunger-regulating hormones at the same time: GLP-1 and GIP. Think of it as Semaglutide with a second engine. GLP-1 tells your brain you are full and slows your stomach. GIP does something different — it works directly on fat cells and helps your body use insulin more efficiently. Together, these two signals produce weight loss results that no single-receptor drug has matched in clinical trials. In SURMOUNT-1, the largest obesity trial of its kind, participants lost an average of 20.9% of their body weight — roughly 52 pounds — in 72 weeks.

Mechanism of action

Tirzepatide works on two separate receptor systems simultaneously. The GLP-1 receptor activation is similar to Semaglutide: it tells your brain you are full, slows gastric emptying, and helps your pancreas release insulin when blood sugar rises. The GIP receptor activation is what makes Tirzepatide unique. GIP works directly on fat tissue to reduce fat storage, improves how efficiently your body uses insulin, and appears to amplify the appetite-suppressing effects of GLP-1. The combination produces a synergistic effect — the two signals together are more powerful than either one alone. This is why Tirzepatide consistently outperformed Semaglutide in head-to-head comparisons (SURMOUNT-5 trial: 47% more weight loss vs Semaglutide 2.4mg).

Benefits discussed in research

  • Up to 20.9% body weight loss in 72 weeks (SURMOUNT-1)
  • Average of 52 lbs lost at the highest dose
  • Significant A1C reduction (up to 2.3%) in type 2 diabetes
  • Dual GIP + GLP-1 receptor activation for synergistic effect
  • Reduces appetite, cravings, and caloric intake
  • Improves insulin sensitivity and beta-cell function
  • Cardiovascular risk reduction (SURPASS-CVOT data)
  • FDA approved for type 2 diabetes (Mounjaro) and obesity (Zepbound)

Research status

FDA Approved

Dosing information

For educational and research purposes only. Not medical advice.

typical
5–15 mg per week (maintenance)
range
2.5 mg (starting) to 15 mg (maximum)
frequency
Once weekly
route
Subcutaneous injection
cycleLength
Ongoing (chronic use)
notes
Start at 2.5 mg once weekly for 4 weeks. Increase by 2.5 mg every 4 weeks as tolerated: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Most people reach their maintenance dose between weeks 16–20. Slow titration is key to minimizing GI side effects. Requires a prescription.

Side effects and safety

  • Nausea (most common, especially during dose increases)
  • Diarrhea
  • Vomiting
  • Constipation
  • Decreased appetite
  • Injection site reactions
  • Potential pancreatitis (rare)
  • Thyroid C-cell tumors (theoretical, based on animal studies — same warning as all GLP-1 drugs)
  • Hypoglycemia (rare, mainly when combined with insulin or sulfonylureas)

Frequently asked questions

How does Tirzepatide compare to Semaglutide (Ozempic/Wegovy)?

Tirzepatide consistently produces more weight loss than Semaglutide in clinical trials. In SURMOUNT-1, the top dose of Tirzepatide achieved 20.9% weight loss vs approximately 15% for Semaglutide at its top dose. The SURMOUNT-5 head-to-head trial showed Tirzepatide produced 47% more weight loss than Semaglutide 2.4mg. The key difference is the second receptor: Tirzepatide hits both GLP-1 and GIP, while Semaglutide only targets GLP-1.

How long does it take to see results with Tirzepatide?

Most people notice reduced appetite within the first 1–2 weeks. Meaningful weight loss typically becomes visible by weeks 8–12. The maximum weight loss effect builds over 36–72 weeks as the dose increases. In SURMOUNT-1, participants were still losing weight at week 72, suggesting the plateau had not yet been reached for many.

What is the difference between Mounjaro and Zepbound?

They are the same drug — Tirzepatide — with different FDA approvals. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management in adults with obesity or overweight with a weight-related condition. The dosing and formulation are identical; the difference is the approved indication and the brand name.

Will I regain weight if I stop Tirzepatide?

Yes, most people regain weight after stopping. SURMOUNT-4 data showed that participants who stopped Tirzepatide after 36 weeks regained about two-thirds of their lost weight over the next 52 weeks. This is not a failure of the drug — it reflects that obesity is a chronic condition. Tirzepatide manages the hormonal signals that drive hunger; when you stop, those signals return. Building sustainable habits while on the medication is essential.

How does Tirzepatide relate to Retatrutide?

Retatrutide is the next generation after Tirzepatide. While Tirzepatide targets two receptors (GLP-1 + GIP), Retatrutide targets three (GLP-1 + GIP + Glucagon). That third receptor — glucagon — boosts metabolism and energy expenditure, which is why early Phase 3 data shows Retatrutide producing even greater weight loss (16.8% in 40 weeks, still climbing at trial end). Tirzepatide is FDA-approved and available now; Retatrutide is in Phase 3 trials.

Is Tirzepatide safe for people without diabetes?

Yes. Zepbound (Tirzepatide) is FDA-approved specifically for adults with obesity or overweight with at least one weight-related health condition, regardless of diabetes status. The SURMOUNT-1 trial enrolled people without diabetes and showed the same strong weight loss results. Always work with a licensed provider to determine if it is appropriate for your situation.

Research references

Read the Tirzepatide profile

Triple Regulator "Reta"

Next-generation triple hormone agonist with the most powerful weight loss data ever recorded in a clinical trial

Retatrutide is Eli Lilly's experimental triple hormone receptor agonist — and the most powerful weight loss compound ever tested in a large-scale clinical trial. While Ozempic (semaglutide) targets one hormone receptor and Mounjaro (tirzepatide) targets two, retatrutide hits three at once: GLP-1, GIP, and glucagon. That third receptor — glucagon — is the game-changer. It does not just reduce how much you eat; it actively boosts your metabolism and increases the energy your body burns at rest. In the Phase 2 trial, participants lost up to 24% of their body weight over 48 weeks. In the TRIUMPH-4 Phase 3 obesity trial (results announced December 2025), participants on 12 mg weekly lost an average of 28.7% of their body weight — that is 71.2 pounds on an average starting weight of 248 lbs — over 68 weeks. 58% of participants on the highest dose achieved at least 25% weight loss. One in eight reported complete resolution of osteoarthritis knee pain. A separate Phase 3 trial in type 2 diabetes showed 16.8% weight loss (36.6 lbs) in just 40 weeks, with A1C reductions of 1.7–2.0%. Retatrutide is not yet FDA approved — an NDA submission is expected in Q4 2026 with approval projected for late 2027 — but it is already considered the next major leap in metabolic medicine.

Mechanism of action

Retatrutide works through three simultaneous hormone pathways, which is what makes it uniquely powerful. First, it activates GLP-1 receptors in the brain and gut — the same pathway as Ozempic — to suppress appetite, slow gastric emptying, and improve insulin secretion. Second, it activates GIP receptors — the same second pathway as Mounjaro — to enhance insulin sensitivity and fat metabolism. Third, and most importantly, it activates glucagon receptors in the liver and fat tissue. Glucagon is a hormone that normally raises blood sugar and increases energy expenditure. By activating glucagon receptors alongside GLP-1 (which counterbalances the blood sugar effect), retatrutide gets the metabolic boost of glucagon without the blood sugar spike. The result is a compound that reduces how much you eat AND increases how much energy your body burns — a combination no single or dual agonist can match.

Benefits discussed in research

  • TRIUMPH-4 Phase 3 (obesity): 28.7% body weight loss — average 71.2 lbs — over 68 weeks
  • 58% of participants on 12 mg achieved at least 25% weight loss
  • Phase 3 (T2D): 16.8% body weight loss (36.6 lbs) in 40 weeks with A1C drop of 1.7–2.0%
  • Phase 2: up to 24.2% body weight loss over 48 weeks
  • Enhanced energy expenditure via glucagon receptor activation — not just appetite suppression
  • Significant reduction in visceral fat, liver fat (MASLD/MASH potential)
  • Improved cardiovascular markers: triglycerides, blood pressure, LDL-C
  • One in eight participants reported complete resolution of osteoarthritis knee pain
  • Weight loss was still progressing at end of TRIUMPH-4 trial — no plateau observed

Research status

Phase III

Dosing information

For educational and research purposes only. Not medical advice.

typical
4 mg once weekly (Phase 3 mid-dose)
range
1 mg (starting) to 12 mg (highest studied dose)
frequency
Once weekly
route
Subcutaneous injection (abdomen preferred; thighs or upper arms also acceptable)
cycleLength
12–48 weeks (Phase 3 ran 40 weeks)
notes
Phase 3 trial used doses of 4 mg, 8 mg, and 12 mg weekly. Start at 1–2.5 mg once weekly for the first 4 weeks, then titrate up by 0.5 mg increments every 4–6 weeks as tolerated. Slow titration is critical to minimize GI side effects. Not yet FDA approved — currently research use only.

Reconstitution and storage

For an educational calculation using a labeled 12 mg vial and a final volume of 1 mL, the concentration is 12 mg/mL. Check the actual product label and follow qualified professional guidance; this example is not a preparation or treatment instruction.

Lyophilized powder: store in a cool, dry, dark area for up to 1 year. Once reconstituted: refrigerate and use within 45–60 days.

Side effects and safety

  • Nausea (most common, especially during dose titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Injection site reactions
  • Constipation
  • Fatigue (mild)

Frequently asked questions

What did the Phase 3 TRIUMPH-4 trial show for Retatrutide?

The TRIUMPH-4 Phase 3 trial, focused on adults with obesity (average starting weight 248 lbs, BMI 40), showed that participants on 12 mg weekly lost an average of 28.7% of their body weight — about 71.2 pounds — over 68 weeks. The 9 mg dose produced 26.4% weight loss. The placebo group lost just 2.1%. 58% of participants on 12 mg achieved at least 25% weight loss, and nearly 24% achieved 35% or more. One in eight participants reported complete resolution of osteoarthritis knee pain. Weight loss was still progressing at the end of the trial with no plateau in sight. A separate Phase 3 trial in type 2 diabetes showed 16.8% weight loss (36.6 lbs) in 40 weeks with A1C reductions of 1.7–2.0%.

How does Retatrutide compare to Semaglutide (Ozempic/Wegovy)?

Semaglutide targets one hormone receptor (GLP-1). Retatrutide targets three simultaneously (GLP-1, GIP, and glucagon). In Phase 2 trials, Retatrutide produced up to 24% body weight loss over 48 weeks, compared to about 15% for semaglutide over a similar period. The addition of glucagon receptor activation is the key difference — it boosts metabolism and energy expenditure in a way semaglutide cannot. Think of it as the next generation of the same class, but with a significantly upgraded engine.

How does Retatrutide compare to Tirzepatide (Mounjaro/Zepbound)?

Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a dual agonist targeting GLP-1 and GIP. Retatrutide adds a third receptor — glucagon — on top of those two. Phase 2 data suggests Retatrutide produces greater weight loss than tirzepatide, though head-to-head trials have not yet been completed. Both are from Eli Lilly, and Retatrutide is essentially the next evolution of the tirzepatide platform.

Is Retatrutide FDA approved?

No. As of early 2026, Retatrutide is still in Phase 3 clinical trials and has not received FDA approval. Obesity-specific Phase 3 trial results are expected later in 2026. It is currently available for research use only and requires a prescription in jurisdictions where compounding is permitted.

What is the starting dose for Retatrutide?

Based on Phase 3 trial protocols, start at 1–2.5 mg once weekly for the first 4 weeks. Increase by 0.5 mg increments every 4–6 weeks as tolerated. The Phase 3 trial used doses of 4 mg, 8 mg, and 12 mg weekly as maintenance doses. The abdomen is the preferred injection site for consistent absorption.

What concentration does a 12 mg Retatrutide example yield at a final volume of 1 mL?

For an educational calculation, 12 mg in a final volume of 1 mL equals 12 mg/mL. The calculator can show volume equivalents, but it does not establish a safe or appropriate preparation or dose. Refer to the actual label and qualified professional guidance.

How long can I store reconstituted Retatrutide?

Lyophilized (freeze-dried) powder can be stored in a cool, dry, dark area for up to 1 year. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 45–60 days. Never freeze reconstituted peptide and protect from direct light.

What conditions is Retatrutide being studied for?

Active Phase 3 trials are studying Retatrutide for obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD/NASH). Phase 2 data also showed significant reductions in liver fat content, suggesting potential as a treatment for metabolic-associated steatohepatitis (MASH). Obesity-specific Phase 3 results are expected in late 2026.

Research references

Read the Triple Regulator "Reta" profile

More comparisons